Hims Hers Health Inc (HIMS)vsTakeda Pharmaceutical Co Ltd ADR (TAK)
HIMS
Hims Hers Health Inc
$22.02
-8.86%
HEALTHCARE · Cap: $5.67B
TAK
Takeda Pharmaceutical Co Ltd ADR
$17.82
-1.60%
HEALTHCARE · Cap: $57.56B
Smart Verdict
WallStSmart Research — data-driven comparison
Takeda Pharmaceutical Co Ltd ADR generates 190073% more annual revenue ($4.46T vs $2.35B). HIMS leads profitability with a 5.5% profit margin vs 2.5%. TAK appears more attractively valued with a PEG of 0.40. TAK earns a higher WallStSmart Score of 60/100 (C).
HIMS
Hold50
out of 100
Grade: D+
TAK
Buy60
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-538.6%
Fair Value
$3.47
Current Price
$22.02
$18.55 premium
Margin of Safety
-77.5%
Fair Value
$10.30
Current Price
$17.82
$7.52 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 25 in profit
Revenue surging 28.4% year-over-year
Growing faster than its price suggests
Reasonable price relative to book value
Every $100 of equity generates 150 in profit
Earnings expanding 330.2% YoY
Generating 317.5B in free cash flow
Large-cap with strong market position
Areas to Watch
Trading at 9.3x book value
Distress zone — elevated risk
5.5% margin — thin
Operating margin of 2.7%
4.2% revenue growth
2.5% margin — thin
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : HIMS
The strongest argument for HIMS centers on Return on Equity, Revenue Growth. Revenue growth of 28.4% demonstrates continued momentum.
Bull Case : TAK
The strongest argument for TAK centers on PEG Ratio, Price/Book, Return on Equity. PEG of 0.40 suggests the stock is reasonably priced for its growth.
Bear Case : HIMS
The primary concerns for HIMS are Price/Book, Altman Z-Score, Profit Margin. A P/E of 48.8x leaves little room for execution misses. Debt-to-equity of 2.34 is elevated, increasing financial risk.
Bear Case : TAK
The primary concerns for TAK are Revenue Growth, Profit Margin, P/E Ratio. A P/E of 82.8x leaves little room for execution misses. Thin 2.5% margins leave little buffer for downturns.
Key Dynamics to Monitor
HIMS profiles as a growth stock while TAK is a value play — different risk/reward profiles.
HIMS carries more volatility with a beta of 2.61 — expect wider price swings.
HIMS is growing revenue faster at 28.4% — sustainability is the question.
TAK generates stronger free cash flow (317.5B), providing more financial flexibility.
Bottom Line
TAK scores higher overall (60/100 vs 50/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Hims Hers Health Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers with licensed healthcare professionals. The company is headquartered in San Francisco, California.
Visit Website →Takeda Pharmaceutical Co Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture and marketing of pharmaceuticals, over-the-counter drugs and quasi-drug consumer products, and other health care products. The company is headquartered in Tokyo, Japan.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?